Intravenous platelet blockade with cangrelor during PCI Academic Article uri icon

Overview

MeSH Major

  • Acute Coronary Syndrome
  • Adenosine Monophosphate
  • Angioplasty, Balloon, Coronary
  • Platelet Aggregation Inhibitors

abstract

  • The use of periprocedural cangrelor during PCI was not superior to placebo in reducing the primary end point. The prespecified secondary end points of stent thrombosis and death were lower in the cangrelor group, with no significant increase in the rate of transfusion. Further study of intravenous ADP blockade with cangrelor may be warranted. (ClinicalTrials.gov number, NCT00385138.)

publication date

  • December 10, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa0908629

PubMed ID

  • 19915222

Additional Document Info

start page

  • 2330

end page

  • 41

volume

  • 361

number

  • 24